- Opinion
- [Reporter’s view] The reality of dispensing separation
- by Jung, Heung-Jun Jul 21, 2020 06:10am
- COVID-19 caused a lot of concerns in the first half of this year in outpatient pharmacies and it was also a time for indirect evaluation, revealing the negative aspect of dispensing separation. Most pharmacies are complaining of deterioration in management due to COVID-19 , and the damage to pharmacies which receive many prescriptions is e
- Company
- Complaint on how NHIS unveiled pricing negotiation guideline
- by Eo, Yun-Ho Jul 20, 2020 06:19am
- The pharmaceutical industry in Korea is complaining on how National Health Insurance Service (NHIS) announced the drug pricing negotiation guideline. According to the industry sources, Korean Research-based Pharmaceutical Industry Association (KRPIA) has recently submitted a statement to NHIS regarding the public opinion collection proced
- Policy
- Generic exclusivity is on the verge of change
- by Lee, Tak-Sun Jul 20, 2020 06:19am
- The system of generic exclusivity, which grants the monopoly of the market for 9 months to patented generic drugs, is on the verge of change. It is expected that the measures to improve the right to generic exclusivity that were promoted through the public-private council will soon reveal its outline. As the process of the meeting is delay
- Policy
- Integrating PMS with RMP to protect new drug information
- by Lee, Tak-Sun Jul 20, 2020 06:19am
- The post-marketing surveillance (PMS) system that monitors new drug’s adverse reaction experienced by patients to maintain the drug safety would be integrated with the risk management plan (RMP) review system. The number of investigated subjects would be reasonably adjusted and the data protection system for the authorized new drug woul
- Company
- Prescription performance has been recovering since June
- by Chon, Seung-Hyun Jul 20, 2020 06:19am
- The overall outpatient prescription growth in the first half of this year has slowed. It remained at the same level as last year in the aftermath of COVID-19. However, prescription performance has been recovering since June, unlike April and May. As the fear of COVID-19 spread in the first quarter, patients received prescriptions all at on
- Policy
- Minister Park is trying to preliminarily secure Remdesivir
- by Lee, Jeong-Hwan Jul 20, 2020 06:19am
- Minister Park Neung-Hoo, from the MOHW said he is trying to maximize the estimated number of seriously ill patients in Korea to preliminarily secure the Remdesivir, known as a cure for COVID-19. One of the criteria for the distribution of Remdesivir around the world is the number of seriously ill patients, so it aims to do its best to ensu
- Product
- Eventually, Fulcare’s YouTube Ad is deleted
- by Jung, Heung-Jun Jul 20, 2020 06:18am
- When Mennarini Korea's athlete's foot drug Fulcare’s YouTube advertisement raised a problem saying that Ads excluded pharmacist skills, the pharmaceutical company deleted the video and began to rectify it. The content of the controversial advertisement is a scene where Another patient who was waiting for a patient who visited the pharmac
- Company
- Rx of NOAC is recommended in COVID-19 epidemic
- by Eo, Yun-Ho Jul 17, 2020 05:55am
- The need for prescription of New Oral Anti-Coagulant (NOAC) is also emerging in COVID-19 outbreak. NOAC does not require periodic INR (International Normalized Ratio) monitoring, thus reducing visits to clinics unlike Warfarin. For this reason, NOAC is a good treatment option for patients who are unable to go to the hospital or need long-t
- Company
- Korean-made IMD Rosuzet and Zemimet prevail over COVID-19
- by An, Kyung-Jin Jul 17, 2020 05:55am
- Apparently a number of incrementally modified drugs (IMDs) developed with Korean-made technology excelled in the prescription drug market amid novel coronavirus (COVID-19) pandemic. A dyslipidemia combination drug Rosuzet and an antidiabetic combination drug Zemiglo recorded two-digit growth and settled on the top chart in the prescrip
- Policy
- Generic pricing negotiation from Sept to protect patients
- by Lee, Hye-Kyung Jul 17, 2020 05:55am
- Korea’s National Health Insurance Service (NHIS) plans to negotiate pricing on generics from September. On July 15, NHIS submitted briefing material for the National Assembly provisional session that elaborated the outcomes of the healthcare coverage enhancement (Moon Jae-in Care) and the government’s prospective plan to lower medical
